XEN-445
CAS No. 1515856-92-4
XEN-445 ( XEN445; XEN 445; XEN-445 )
产品货号. M17330 CAS No. 1515856-92-4
XEN445, a potent and selective endothelial lipase(EL) inhibitor (IC50=0.237 uM), exhibitis good ADME and PK properties.
纯度: 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥275 | 有现货 |
|
5MG | ¥446 | 有现货 |
|
10MG | ¥851 | 有现货 |
|
25MG | ¥1604 | 有现货 |
|
50MG | ¥2989 | 有现货 |
|
100MG | ¥4625 | 有现货 |
|
500MG | ¥9963 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称XEN-445
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述XEN445, a potent and selective endothelial lipase(EL) inhibitor (IC50=0.237 uM), exhibitis good ADME and PK properties.
-
产品描述XEN445 is potent and selective endothelial lipase inhibitor, that showed good ADME and PK properties, and demonstrated in vivo efficacy in raising plasma HDLc concentrations in mice. Endothelial lipase (EL) activity has been implicated in HDL metabolism and in atherosclerotic plaque development; inhibitors are proposed to be efficacious in the treatment of dyslipidemia related cardiovascular disease.
-
同义词XEN445; XEN 445; XEN-445
-
通路Endocrinology/Hormones
-
靶点5-HT Receptor
-
受体endothelial lipase
-
研究领域Cardiovascular Disease
-
适应症——
化学信息
-
CAS Number1515856-92-4
-
分子量366.33
-
分子式C18H17F3N2O3
-
纯度98%
-
溶解度DMSO : ≥ 40 mg/mL. 109.19 mM
-
SMILESc1(ccc(c(c1)C(=O)O)N1C[C@H](CC1)OCc1ncccc1)C(F)(F)F
-
化学全称(S)-2-(3-(pyridin-2-ylmethoxy)pyrrolidin-1-yl)-5-(trifluoromethyl)benzoic acid
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Sun S, et al. Bioorg Med Chem. 2013, 21(24), 7724-7734.
产品手册
关联产品
-
N-Acetyl-5-hydroxytr...
N-Acetylserotonin (NAS), also known as normelatonin, is a naturally occurring chemical intermediate in the endogenous production of melatonin from serotonin.
-
Chlorprothixene
Chlorprothixene is a typical antipsychotic drug of the thioxanthene class and was the first of the series to be synthesized.
-
Pergolide mesylate s...
PERGOLIDE MESYLATE is a long-acting dopamine agonist which has been used to treat parkinson disease and hyperprolactinemiabut withdrawn from some markets due to potential for heart valve diseases.